Adage Capital Management, L.P. sold $33M of PRAX
owner at Praxis Precision Medicines, Inc.. 313,910 shares at an average of $105.76, traded Oct 16, 2025, filed Oct 17, 2025.
Score components
- +12Role10% owner
- +25Trade size$33.2M at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.9%, 3m +67.0%, 6m +80.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-25-004455, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2025 | SOpen-market sale Common Stock, $0.0001 par value per share ("Common Stock")indirect: See footnotes | +12,600 | $90.00 | $1.1M | 2,361,485 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +447 | $91.04 | $41k | 2,361,038 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +1,363 | $92.03 | $125k | 2,359,675 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +559 | $100.11 | $56k | 2,359,116 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +27,287 | $101.00 | $2.8M | 2,331,829 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +250,000 | $104.31 | $26M | 2,081,829 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +1,661 | $130.10 | $216k | 2,080,168 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +487 | $131.64 | $64k | 2,079,681 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +308 | $132.19 | $41k | 2,079,373 | Oct 17, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: See footnotes | +19,198 | $140.00 | $2.7M | 2,060,175 | Oct 17, 2025 |
Related signals
Other insiders at Praxis Precision Medicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Praxis Precision Medicines, Inc. | Jill DeSimone director | $3.6M 11,600 shares | -83% | |
| 53Moderate | Praxis Precision Medicines, Inc. | Lauren Mastrocola Principal Accounting Officer | $2.6M 13,600 shares | -57% | |
| 53Moderate | Praxis Precision Medicines, Inc. | Alex Nemiroff General Counsel and Secretary | $4.9M 25,130 shares | -55% | |
| 34Weak | Praxis Precision Medicines, Inc. | Lauren Mastrocola Principal Accounting Officer | $424k 5,188 shares | -48% | |
| 38Weak | Praxis Precision Medicines, Inc. | Alex Nemiroff General Counsel and Secretary | $661k 8,239 shares | -44% | |
| 39Weak | PRAXbuy Praxis Precision Medicines, Inc. | Marcio Souza Chief Executive Officer | $11k 10,000 shares | +29% | |
| 61Notable | Praxis Precision Medicines, Inc. | Timothy Edwin Kelly Chief Financial Officer | $6,998 8,000 shares | +21% | |
| 61Notable | Praxis Precision Medicines, Inc. | Timothy Edwin Kelly Chief Financial Officer | $6,998 8,000 shares | +21% | |
| 64Notable | Praxis Precision Medicines, Inc. | Dean J Mitchell director | $42k 50,000 shares | +200% | |
| 71Notable | Praxis Precision Medicines, Inc. | Marcio Souza Chief Executive Officer | $60k 70,002 shares | +37% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.